Firategrast for relapsing remitting MS trial reported
Posted: Thu Jan 12, 2012 1:57 am
Summary
Background
Monoclonal antibody therapy against α4β-integrin is efficacious in patients with multiple sclerosis (MS) with some safety concerns. We assessed the safety and efficacy of firategrast, a small oral anti-α4β-integrin molecule, in patients with relapsing remitting MS....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397